ArticleScientific reports2017
Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Cell and tissue engineering in lymph nodes for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- Chemokine/cytokine-releasing biomaterials induce in situ tertiary lymphoid-like structures and enhance antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming.Journal for immunotherapy of cancer · 2025Article
- An Introduction to Tertiary Lymphoid Structures in Cancer.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Targeting lymph nodes for enhanced cancer vaccination: From nanotechnology to tissue engineering.Materials today. Bio · 2024Review
- Article
- Cancer-Associated B Cells in Sarcoma.Cancers · 2023Review
- Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma.Frontiers in immunology · 2023Review
- Integrative lymph node-mimicking models created with biomaterials and computational tools to study the immune system.Materials today. Bio · 2022Review
- Tertiary Lymphoid Structures in Cancer: The Double-Edged Sword Role in Antitumor Immunity and Potential Therapeutic Induction Strategies.Frontiers in immunology · 2021Review
- Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model.Cancer immunology, immunotherapy : CII · 2020Article
- Tertiary lymphoid structures in the era of cancer immunotherapy.Nature reviews. Cancer · 2019Review
- Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies.Frontiers in physics · 2019Article
- Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.Frontiers in immunology · 2019Review
- Role of chemokines in ectopic lymphoid structures formation in autoimmunity and cancer.Journal of leukocyte biology · 2018Review
- Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line.Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The induction of ectopic lymph node structures (ELNs) holds great promise to augment immunotherapy against multiple cancers including metastatic melanoma, in which ELN formation has been associated with a unique immune-related gene expression signature composed of distinct chemokines. To investigate the therapeutic potential of ELNs induction, preclinical models of ELNs are needed for interrogation of these chemokines. Computational models provide a non-invasive, cost-effective method to investigate leukocyte trafficking in the tumor microenvironment, but parameterizing such models is difficult due to differing assay conditions and contexts among the literature. To better achieve this, we systematically performed microchemotaxis assays on purified immune subsets including human pan-T cells, CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.